G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
Correlates of acute renal failure in patients receiving parenteral amphotericin B.
David W. Bates,Ling Su,Ling Su,Ling Su,Donghui T. Yu,Donghui T. Yu,Donghui T. Yu,Glenn M. Chertow,Glenn M. Chertow,Glenn M. Chertow,Diane L. Seger,Diane L. Seger,Diane L. Seger,Daniel R.J. Gomes,Daniel R.J. Gomes,Daniel R.J. Gomes,Richard Platt,Richard Platt,Richard Platt +18 more
TL;DR: Correlates of ARF at the beginning and during the course of amphotericin therapy were identified and then combined to allow stratification according to ARF risk, and provide evidence for guidelines for the selection of patients for alternative therapies.
Journal ArticleDOI
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
David C. Wheeler,Gérard M. London,Patrick S. Parfrey,Geoffrey A. Block,Ricardo Correa-Rotter,Bastian Dehmel,Tilman B. Drüeke,Jürgen Floege,Yumi Kubo,Kenneth W. Mahaffey,William G. Goodman,Sharon M. Moe,Marie Louise Trotman,Safa Abdalla,Glenn M. Chertow,Charles A. Herzog +15 more
TL;DR: Accepting the limitations of post hoc analysis, any benefits of cinacalcet on cardiovascular disease in the context of hemodialysis may result from attenuation of nonatherosclerotic processes.
Journal ArticleDOI
Randomized trial of intravenous iron-induced hypophosphatemia
TL;DR: Ferric carboxymaltose rapidly increases biologically active FGF23 in patients with iron deficiency anemia, which was significantly associated with contemporaneous hypophosphatemia, renal phosphate wasting, and decreased serum calcitriol and calcium, and increased PTH concentrations.
Journal ArticleDOI
The Phosphate Binder Equivalent Dose
TL;DR: The phosphate‐binding equivalent dose may be useful in comparing changes in phosphate binder prescription over time when multiple binders are being prescribed, when estimating an initial binder prescriptions, and also in phosphate kinetic modeling.
Journal ArticleDOI
Determinants of physical performance in ambulatory patients on hemodialysis.
TL;DR: Physical performance is significantly impaired in ambulatory hemodialysis patients and is related to age, serum albumin, and dialysis dose, according to a cross-sectional analysis of patients treated at three University of California San Francisco-affiliated dialysis units.